Medivir has announced the launch of Adasuve inhaled loxapine for the treatment of agitation in schizophrenic or bipolar patients in Sweden, Norway, Finland, and Denmark. Medivir acquired the rights to commercialize Adasuve in all five Nordic countries from Grupo Ferrer in September 2013. Medivir Executive VP, Commercial, Henrik Krook, commented, “It is gratifying … [Read more...] about Medivir launches Adasuve in four Nordic countries
Business
VR1 presents poster on intranasal capsaicin for headache
The makers of a homeopathic capsaicin nasal spray are presenting a poster featuring "real-world patient case series analysis supporting the use of intranasal capsaicin as an effective rapid treatment for severe headache and migraine pain" at the 2014 American Academy of Neurology (AAN) Annual Meeting. VR1, Inc. recently launched an intranasal capsaicin product, … [Read more...] about VR1 presents poster on intranasal capsaicin for headache
Anoro Ellipta launched in the US
GSK and Theravance have announced the launch of Anoro Ellipta umeclidinium/vilanterol inhalation powder in the United States, triggering a $30 million milestone payment from Theravance to GSK. The FDA approved Anoro Ellipta for the treatment of COPD in December 2013. Senior VP of GSK's Respiratory Business Unit Jorge Bartolome commented, "We understand that COPD … [Read more...] about Anoro Ellipta launched in the US
Theravance announces $450 million in financing
Theravance has announced that its LABA Royalty Sub wholly owned subsidiary "issued $450 million in aggregate principal amount of PhaRMA 9% Notes due on or before May 15, 2029. The notes are secured by a security interest in a segregated bank account established to receive 40% of royalties from global net sales of Relvar/Breo Ellipta (fluticasone furoate/vilanterol … [Read more...] about Theravance announces $450 million in financing
OPKO Health acquires Inspiro Medical and its Inspiromatic DPI
US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study of the device used to deliver formoterol. OPKO CEO and Chairman Phillip Frost said, "We are pleased to add this next generation … [Read more...] about OPKO Health acquires Inspiro Medical and its Inspiromatic DPI
Molecular Profiles looks to increase US business
CDMO Molecular Profiles says that it has hired Charles D. Maher as head of US sales in order to "increase awareness and uptake of its pharmaceutical development services in the North American market." The company's services include formulation development and clinical trial manufacturing of dry powder inhalers. Molecular Profiles CEO Nikin Patel commented, "Over … [Read more...] about Molecular Profiles looks to increase US business
Prosonix licenses two MDIs to Mylan
Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK's Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs, PSX1001 and PSX1050, with the same particle engineered formulation of fluticasone; PSX1050 differs from PSX1001 only in having a dose … [Read more...] about Prosonix licenses two MDIs to Mylan
Hovione gets US patent for XCaps inhaler
According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the inhaler in September, 2013. Hovione VP Peter Villax, who is a co-inventor of the DPI, commented, “We give our customers an edge in speed of … [Read more...] about Hovione gets US patent for XCaps inhaler
Meda rejects Mylan offer
Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, "All continued discussions between Meda and Mylan have been terminated without further actions." In June 2013, Meda denied that it was in talks to be acquired by Sun Pharmaceuticals. Meda's products … [Read more...] about Meda rejects Mylan offer
Recipharm begins trading on Stockholm stock exchange
Swedish CDMO Recipharm, which has a dedicated DPI manufacturing facility in the UK, has begun trading on the Stockholm stock exchange, according to NASDAQ OMX. Recipharm had announced the IPO in March 2014. Recipharm CEO Thomas Eldered said, “Today marks the beginning of a new phase in Recipharm’s life. We welcome all our new shareholders who have demonstrated their … [Read more...] about Recipharm begins trading on Stockholm stock exchange